Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||TGFbDNRII-transduced autologous TILs|
TGFbDNRII-transduced autologous TILs are patient-derived tumor infiltrating lymphocytes engineered to express a dominant negative version of transforming growth factor beta receptor (TGFbDNRII), which potentially results in enhanced anti-tumor immune activity (NCI Drug Dictionary).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs||Aldesleukin Cyclophosphamide Fludarabine NGFR-transduced autologous T lymphocytes TGFbDNRII-transduced autologous TILs||0||1|
|Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + TGFbDNRII-transduced autologous TILs||Anti-NY ESO-1 mTCR PBL Cyclophosphamide TGFbDNRII-transduced autologous TILs||0||1|
|TGFbDNRII-transduced autologous TILs||TGFbDNRII-transduced autologous TILs||0||0|